On Jan. 17, the Drug Enforcement Administration published a final rule, “Continuity of Care via Telemedicine for Veterans Affairs Patients.” The final rule includes several key provisions. Telemedicine Prescribing of Controlled Substances VA practitioners can prescribe Schedule II–V controlled substances via telemedicine without [...]
Early career registered sleep technologists are invited to apply for a new autoscoring Gold Standard Panel that will support the AASM’s efforts to provide oversight and certify autoscoring sleep scoring packages, helping to move the field of sleep medicine forward. The AASM Autoscoring Certification [...]
On Jan. 3, the Centers for Medicare & Medicaid Services (CMS) announced that Merit-Based Incentive Payment System (MIPS) submissions for the Quality Payment Program (QPP) can now be submitted and updated through 8 p.m. ET on March 31, 2025. The AASM has developed the [...]
Whether you're celebrating a once-in-a-lifetime victory or lamenting a heartbreaking loss, chances are you'll stay up later than usual on Super Bowl Sunday — leaving you less rested come Monday. In fact, new survey data from the American Academy of Sleep Medicine finds that [...]
The Centers for Medicare & Medicaid Services (CMS) has posted the revised resource, “How to Use the Office & Outpatient Evaluation and Management Visit Complexity Add-On Code G2211.” The code G2211 reflects visit complexity and increases the value of office and outpatient evaluation and [...]
A recent survey from the American Academy of Sleep Medicine highlights a surprising paradox: 81% of Americans report losing sleep due to worries about sleep problems. This illustrates the growing pressure to achieve “perfect sleep,” fueled by social media trends, wellness products, and sleep [...]
As we get ready to bid farewell to 2024 and welcome the arrival of a new year, the American Academy of Sleep Medicine is also preparing to celebrate a significant milestone in 2025: This year we recognize the AASM 50th anniversary! Considering how our [...]
On Dec. 20, Eli Lilly announced the Food and Drug Administration has approved the injectable prescription medicine Zepbound (tirzepatide) for adults with moderate-to-severe obstructive sleep apnea and obesity. The American Academy of Sleep Medicine provides the following statement for patients and clinicians. AASM statement [...]
On Dec. 20, Eli Lilly announced the FDA has approved Zepbound (tirzepatide) as the first and only prescription medication for adults with moderate-to-severe obstructive sleep apnea and obesity. Read the FDA press release announcing Zepbound's approval for sleep apnea. The American Academy of Sleep [...]
In response to ongoing advocacy from the AASM and many other medical organizations, the Drug Enforcement Administration (DEA), in concert with the Department of Health and Human Services (HHS), has issued a third extension of telemedicine flexibilities for the prescribing of controlled medications through [...]